|
業務類別
|
Biotechnology |
|
業務概覽
|
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases. |
| 公司地址
| 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265 |
| 電話號碼
| +1 336 841-0300 |
| 傳真號碼
| +1 866 306-5107 |
| 公司網頁
| https://www.vtvtherapeutics.com |
| 員工數量
| 26 |
| Mr. Barry K. Brown |
Chief Accounting Officer |
-- |
19/05/2025 |
| Mr. Paul J. Sekhri |
Executive Chairman of the Board, President and Chief Executive Officer |
美元 673.00K |
28/04/2026 |
| Mr. Richard S. Nelson |
Director, Executive Vice President and Chief Business Officer |
-- |
28/04/2026 |
| Dr. Michael Tung, M.B.A.,M.D. |
Executive Vice president and Chief Financial Officer |
美元 279.55K |
28/04/2026 |
|
|
| Dr. Fahed Al Marzooqi, M.D. |
Independent Director |
28/04/2026 |
| Dr. Anne M. Phillips, M.D. |
Independent Director |
28/04/2026 |
| Mr. Paul J. Sekhri |
Executive Chairman of the Board, President and Chief Executive Officer |
28/04/2026 |
| Mr. Daniel K. Spiegelman |
Independent Director |
28/04/2026 |
| Mr. Richard S. Nelson |
Director, Executive Vice President and Chief Business Officer |
28/04/2026 |
| Dr. Raymond Cheong, PhD |
Independent Director |
28/04/2026 |
| Dr. Srinivas Akkaraju, M.D.,PhD |
Independent Director |
28/04/2026 |
|
|
|
|
